Dr. Divya Bansal Reviews

A 12-year-old street vendor's daughter from rural Bihar, diagnosed with severe aplastic anemia, received a fully matched unrelated donor transplant funded through a hospital charity program. Dr. Bansal adapted the conditioning regimen due to her malnourished state, resulting in a remarkable 9-month recovery with complete donor engraftment and return to school.

A 68-year-old retired diplomat with secondary AML post-chemotherapy for lymphoma underwent a reduced-intensity conditioning transplant from his HLA-haploidentical daughter. Dr. Bansal managed complex drug interactions with his existing cardiac medications, achieving full chimerism with minimal GVHD despite his advanced age.

A 24-year-old professional athlete with relapsed Hodgkin's lymphoma received an autologous transplant after Dr. Bansal designed a high-dose chemotherapy protocol that preserved his renal function critical for his career. He returned to competitive sports within 11 months with modified training regimens.

A 45-year-old single mother from an urban slum with beta-thalassemia major underwent a cord blood transplant after Dr. Bansal secured rare HLA-matched units from international registries. The patient's extended family provided rotational care support during her 6-month hospitalization.

A 33-year-old software engineer with myelodysplastic syndrome developed severe veno-occlusive disease post-transplant. Dr. Bansal pioneered a novel defibrotide protocol combined with therapeutic plasma exchange, leading to complete hepatic recovery despite initial multi-organ dysfunction.

A 57-year-old farmer with primary myelofibrosis received a JAK2 inhibitor-based pre-transplant conditioning regimen designed by Dr. Bansal to reduce his massive splenomegaly. The unconventional approach enabled successful transplant with his sister as donor despite significant HLA mismatch.

A 19-year-old college student with sickle cell disease underwent a non-myeloablative transplant from his matched sibling. Dr. Bansal incorporated extended hydroxyurea therapy pre-transplant to reduce iron overload, resulting in stable mixed chimerism and resolution of sickle crises.

A 62-year-old grandmother with CML in blast crisis received a sequential transplant approach—first autologous to achieve remission, then allogeneic from an unrelated donor. Dr. Bansal's staged strategy overcame initial poor cytogenetic response, leading to molecular remission.

A 8-year-old refugee child with Wiskott-Aldrich syndrome underwent transplant with Dr. Bansal utilizing post-transplant cyclophosphamide to permit haploidentical transplant from his father. The team coordinated with NGOs for long-term immunoglobulin replacement therapy in their home country.

A 29-year-old pregnant woman diagnosed with ALL in second trimester received a modified chemotherapy regimen followed by postpartum transplant. Dr. Bansal coordinated with obstetricians for planned cesarean at 32 weeks, achieving both healthy baby delivery and successful transplant outcome.

A 71-year-old retired teacher with amyloidosis underwent an outpatient-based autologous transplant program designed by Dr. Bansal using daily telehealth monitoring and community nursing support. The innovative model reduced hospital-acquired infections and maintained quality of life.

A 16-year-old with Fanconi anemia received a fludarabine-based reduced toxicity conditioning transplant from his matched unrelated donor. Dr. Bansal managed complex endocrine abnormalities pre-and post-transplant, requiring multidisciplinary care with endocrinology specialists.

A 38-year-old fisherman with chronic GVHD from a prior transplant performed elsewhere was referred to Dr. Bansal for management. She implemented extracorporeal photopheresis combined with ruxolitinib, achieving significant symptom control and tissue repair after 18 months of therapy.

A 52-year-old restaurant owner with multiple myeloma underwent tandem autologous-allogeneic transplant using his identical twin as donor. Dr. Bansal's unique maintenance therapy protocol with carfilzomib and lenalidomide resulted in sustained minimal residual disease-negative status for 4+ years.